PRP Preparation Variables That Change the Final Product
How is platelet-rich plasma prepared for scalp treatment, and which preparation variables change the final product?
Preparation starts at the vein, not at the centrifuge, and by the time the syringe is loaded you've already made half a dozen choices that decide what the patient actually receives. Draw volume, anticoagulant, spin force, how close to the red cell line you harvest, and whether you activate before injecting all move the final product independently. Two clinics can run the same patient's blood on the same morning and inject genuinely different material.
- Draw and anticoagulant: 15 to 60 mL of whole blood into acid citrate dextrose A or sodium citrate.
- Spin protocol: one soft spin up to roughly 900 g, or a second spin at 700 to 1,500 g.
- Platelet concentration: commonly 2 to 8 times a baseline that itself runs 150,000 to 400,000 per microliter.
- Leukocyte and activation status: rich or poor, activated with calcium or left for tissue contact to trigger.
A preparation is defined by its platelet dose, leukocyte content, red cell content, and activation status, so a credible protocol records spin parameters, final volume, and measured concentration instead of trusting the label on the machine.
What steps does the whole blood draw and processing sequence involve before injection?
The whole sequence fits inside an hour, and every step in it is a place where you either protect the product or quietly degrade it. Most protocols recover only about a tenth to a fifth of what you draw as injectate, so the draw volume isn't arbitrary, it's back-calculated from the treatment plan. The steps that get shortchanged in a busy clinic are the ones with no visible penalty.
- Venipuncture: Draw roughly 20 to 60 mL into anticoagulated tubes or a single closed collection syringe.
- Balance and spin: Load tubes in opposing positions with matched fill volumes, since an unbalanced rotor smears the interface and damages the instrument.
- Read the layers: Packed red cells at the bottom, a thin greyish buffy coat above them, straw-colored plasma on top.
- Extract slowly: Lower a spinal needle or pipette to a fixed distance above the red cell line and draw steadily, because suction turbulence pulls red cells into the harvest.
- Second spin or inject: Resuspend the pellet if the protocol calls for it, then use the product promptly while platelet function holds.
- Prep in parallel: Clean the scalp, mark treatment zones, and place anesthesia while the centrifuge runs.
Most protocols recover only about one tenth to one fifth of the draw volume as final injectate, which is why a 20 to 60 mL draw is sized from the planned treatment volume rather than chosen by habit.
How does single-spin versus double-spin centrifugation change platelet yield and concentration?
Two spins aren't just more of one spin, they solve different problems. The first spin protects your recovery rate; the second one buys concentration per milliliter and charges you platelets for it. Here's the trade in plain numbers.
| Criteria | Single Spin | Double Spin |
|---|---|---|
| Spin parameters | A few hundred g up to about 900 g, 5 to 10 min | Adds 700 to 1,500 g for another 10 to 15 min |
| Platelet recovery | Commonly above 70 percent | Falls with every extra transfer and tube wall loss |
| Concentration factor | Roughly 1.5 to 3x baseline | Roughly 4 to 8x baseline |
| Best fit for scalp | Larger draw, gentler handling, comparable absolute dose | Meaningful dose inside the few mL the scalp accepts |
A single soft spin recovers over 70 percent of available platelets at 1.5 to 3 times baseline, while a second spin at 700 to 1,500 g reaches 4 to 8 times baseline by trading recovery percentage for concentration per milliliter.
How is the final platelet concentration measured, and what counts as a therapeutic dose?
Measurement is what turns a preparation into a known quantity, and it's the step most often skipped entirely. Run a small aliquot through the same automated hematology analyzer you'd use for a complete blood count, and run the patient's whole blood alongside it so the baseline comes from today's draw and not an old chart. Concentration factor sounds impressive; absolute dose is the honest number.
A patient with a 160,000 per microliter baseline receiving a fivefold preparation gets less platelet material than a patient at 350,000 receiving a threefold one, so absolute dose, count per microliter multiplied by milliliters injected, is the figure worth recording.
Why does leukocyte content divide preparations into leukocyte-rich and leukocyte-poor categories?
White cells aren't an impurity that sloppy technique lets slip in. They settle in the same thin band as your platelets, directly above the red cell column, so dipping low to catch every last platelet means harvesting neutrophils too, and staying high leaves both behind. That single decision about harvest depth is what creates the two families.
| Criteria | Leukocyte-Rich | Leukocyte-Poor |
|---|---|---|
| Harvest depth | Dips into the buffy coat and toward the red line | Stays above the interface |
| Neutrophil load | Well above whole blood levels | Close to concentrated plasma with platelets |
| What comes with it | Metalloproteinases, reactive oxygen species, proinflammatory cytokines | Minimal proteolytic load |
| Patient experience | More stinging, tenderness and swelling for a day or two | Generally better tolerated |
| Scalp protocol fit | Argued as a useful inflammatory stimulus | What most dermatologic protocols aim for |
Most dermatologic scalp protocols target leukocyte-poor preparations because follicle stimulation is a signaling problem rather than a wound-healing emergency, though the comparative evidence in alopecia is thinner than the confidence on either side of the argument.
What role does the anticoagulant choice play in platelet viability?
Everything in a tube of drawn blood is racing toward a clot, and the anticoagulant is what buys you the twenty minutes the process needs. The citrates work by chelating ionized calcium, and that same calcium removal is why your platelets arrive at the centrifuge with their alpha granules still loaded instead of already spent.
- Acid citrate dextrose A: Adds dextrose and a lower pH, holding membrane integrity through longer windows and two spins.
- Sodium citrate: Chelates calcium effectively, a reasonable choice for a short single-spin workflow.
- Heparin: Poor fit, since it acts on antithrombin, doesn't block activation, and can aggregate platelets.
- The 1:9 ratio: Underfilled tubes over-acidify and impair function; overfilled tubes permit microclots that trap platelets.
The standard one part anticoagulant to nine parts blood ratio is what makes citrate work, and the calcium it chelates at the draw is exactly the calcium that calcium chloride restores if you later choose to activate.
What does exogenous activation with calcium chloride or thrombin do, and when is it skipped?
Activation is the trigger that turns a suspension of quiet platelets into a release of signaling molecules: the platelet changes shape, its alpha granules fuse with the membrane, and growth factors pour into the surrounding fluid alongside fibrin formation. The question isn't whether that happens, it's where you want it to happen. Front-load it in the syringe and you coat plastic with a burst that starts decaying in minutes.
Most contemporary scalp protocols inject unactivated or add calcium chloride only immediately before injection, because in-tissue activation spreads growth factor release across the hours platelets stay trapped in the local fibrin clot.
What differences separate commercial closed kits from open manual tube methods?
The honest framing is that a kit sells you consistency and a manual method sells you control, and both claims hold up partway. Kits engineer the extraction step out of human hands with a floating buoy, a fixed draw port, or a shaped separator gel, so the plasma fraction comes off the same position no matter who's running the machine. Manual methods put that quality control back in your hands, for better and worse.
| Criteria | Closed Commercial Kit | Open Manual Tube Method |
|---|---|---|
| Contamination exposure | Sealed circuit, transfers through ports | Open transfers on the bench |
| Extraction consistency | Fixed by device geometry | Depends on the operator's hand and eye |
| Per-session cost | Meaningful single-use consumable, compounding across a course | Sterile tubes, syringes, a centrifuge you already own |
| Tunability | Fixed recipe per device | Spin parameters, harvest depth, and volume adjustable per case |
| Auditability | Written protocol a new hire can run day one | Lives partly in the hands of whoever's done it longest |
Different kits target different platelet concentrations, leukocyte profiles, and final volumes, so switching device brands changes the product as much as switching between device and manual preparation.
Which patient-side factors alter the composition of the product before any spinning happens?
No centrifuge can concentrate what wasn't in the vein. Baseline counts in healthy adults span close to a threefold range, so two of your patients on identical equipment running an identical protocol can walk out with doses differing by a factor of two or more. Medication is the most modifiable factor here and the one least often asked about.
- Baseline platelet count: Roughly 150,000 to 400,000 per microliter across healthy adults, close to threefold spread.
- Antiplatelet medication: Aspirin blunts function irreversibly for the seven to ten day platelet lifespan; NSAIDs reversibly.
- Supplements: High-dose fish oil, vitamin E, garlic, and ginkgo carry milder but real antiplatelet activity.
- Hydration and lifestyle: Dehydration nominally raises counts per microliter while making the draw harder; smoking alters reactivity.
- Hematologic conditions: Platelet and bleeding disorders, active infection, and malignancy decide eligibility, not adjustment.
A baseline complete blood count before starting a course tells you whether the patient can supply a useful product at all and gives you the denominator that makes every later concentration measurement mean something.
What contamination, handling, and sterility risks arise during preparation?
Because the material is autologous, the reflex is to treat it as inherently safe, and that reflex is exactly what creates the exposure. You're injecting into dozens of puncture sites in a cosmetic setting where the patient's expectation of risk sits near zero. Sort the failures by what they cost, because they aren't equal.
Preparation has to be run as an aseptic procedure rather than a bench task, with a dedicated clean surface, gloves, skin antisepsis at the draw site, closed transfers wherever the equipment allows, and one patient's samples in the workspace at a time.
Why does preparation variability make published trial results difficult to compare?
The literature here is large and unusually unsettled, and preparation variability accounts for a good share of that. Two trials can share a title, an abbreviation, and an indication while one arm tests a twofold leukocyte-rich unactivated preparation and the other a sixfold leukocyte-poor calcium-activated one, with nothing in the naming convention to reveal the gap. When you pool products that incomparable, you get high heterogeneity and a summary effect describing no real treatment.
- Unreported concentration: Many published trials never state the final platelet count that was actually injected.
- Missing spin parameters: Centrifugation speed and duration are frequently omitted, so the product can't be reconstructed.
- Unstated leukocyte and activation status: Two of the four defining axes simply go unrecorded.
- Uncontrolled injection variables: Depth, needle spacing, volume per square centimeter, session interval, and course length all differ.
A properly reported methods section states draw volume, anticoagulant and ratio, centrifuge g-force and time for each spin, final volume, baseline and final platelet counts, leukocyte characterization, activation status, and the injection schedule, and a study omitting most of these isn't necessarily wrong but it is unrepeatable.
How does regulatory classification constrain the way a clinic may prepare the product?
Regulation reaches this procedure sideways, by governing how you handle the blood rather than how you treat the hair. The governing concept in most jurisdictions is minimal manipulation, meaning your processing can't alter the relevant biological characteristics of the blood. Spinning a patient's own blood into its components sits comfortably inside that line, and the line is narrower than clinic marketing often implies.
Clearing a preparation system as a device is not the same as approving a treatment for hair loss, since the only treatments carrying FDA approval for androgenetic alopecia are oral finasteride and topical minoxidil, so this procedure is practiced off-label with the physician carrying the judgment and consent naming that status.
